Vitamin K: Clotting Factors, Warfarin and the Newborn
The "K" comes from the German Koagulation — and that single letter tells you almost everything this vitamin does. Vitamin K is the switch that turns a handful of freshly made clotting factors from useless protein into working machinery. Take it away and the blood loses its ability to clot; that is exactly what warfarin does on purpose, and exactly why every newborn gets an injection of it in the first minutes of life. Learn vitamin K and you have quietly learned the backbone of anticoagulation, one classic poisoning, and one of the most successful public-health interventions ever devised.
An 8-week-old baby, exclusively breastfed and thriving at home, is brought in floppy and vomiting. A scan shows bleeding inside the brain. There is no injury, no fever, no infection to find — just blood where there should be none. The clotting screen tells the story in one line: a markedly prolonged prothrombin time that corrects the moment vitamin K is given. This is vitamin K deficiency bleeding — haemorrhagic disease of the newborn — and it is almost entirely preventable by a single injection at birth that this baby, for whatever reason, never received. In one cot you can see why clinicians treat vitamin K not as an optional supplement but as a drug the newborn body cannot yet make for itself.
What vitamin K actually does
A clotting factor is born incomplete — vitamin K performs the finishing step. The liver manufactures several clotting factors, but they leave the assembly line inactive. To work, each must undergo one specific chemical edit: gamma-carboxylation — the addition of a carboxyl group to particular glutamate residues on the protein. Vitamin K is the essential cofactor for the enzyme (gamma-glutamyl carboxylase) that performs this edit. Why does it matter? Those new carboxyl groups are what let the factor grip calcium (Ca2+), and gripping calcium is what anchors the factor onto the phospholipid surface where clotting happens. No carboxylation, no calcium binding, no clot. The vitamin-K-dependent factors are a set worth memorizing: II (prothrombin), VII, IX and X, plus the natural anticoagulants protein C and protein S.
There is one more piece that makes the whole story turn: recycling. Each time vitamin K helps carboxylate a factor, it is itself oxidized to an inactive epoxide. The body cannot afford to discard it, so an enzyme called vitamin K epoxide reductase (VKOR) regenerates the active, reduced form so it can be used again. Hold onto that enzyme's name — VKOR is the exact point where the most famous anticoagulant in medicine strikes.
Think of each clotting factor as a grappling hook that has to latch onto the vessel wall to build a clot. Straight off the production line the hook has no prongs — it is a smooth, useless rod. Gamma-carboxylation is the step that files the prongs into it; only then can it catch (grip calcium) and hold. Vitamin K is the craftsman doing the filing, and VKOR is the whetstone that keeps re-sharpening the craftsman's tool. Warfarin doesn't smash the hooks — it quietly steals the whetstone, so before long the craftsman can only turn out smooth, pronged-less rods that slide off the wall.
Warfarin: vitamin K's mirror image
Everything warfarin does is vitamin K biochemistry, read backwards. Warfarin inhibits VKOR. With the recycling enzyme blocked, the pool of active reduced vitamin K dries up, gamma-carboxylation stalls, and the liver keeps producing factors II, VII, IX and X — but as inactive, non-functional versions that cannot bind calcium. The result is a controlled, reversible anticoagulation: the blood clots poorly on purpose. Because the effect is measured through these factors, it shows up on the prothrombin time, reported as the INR (international normalized ratio) — the number every warfarin patient lives by. Two practical fingerprints follow directly from the mechanism. First, warfarin is slow to start working: the factors already in the circulation must decay first, over a couple of days, which is why heparin is used to "bridge" the gap at the beginning. Second — and this belongs to the Haematology / antithrombotics chapter — factor VII and protein C have the shortest half-lives, so they fall first, producing a brief early paradoxical pro-clotting window.
This is the cleanest antidote relationship in pharmacology: warfarin depletes usable vitamin K, so vitamin K reverses warfarin. Give phytomenadione (vitamin K1) and you restock the substrate VKOR was starved of, letting the liver resume making functional factors — the INR drifts back down. The one catch is time. Vitamin K doesn't neutralize warfarin in the blood; it lets the liver build new factors from scratch, which takes hours. So for a patient who is actively, dangerously bleeding, vitamin K alone is too slow — you also give the ready-made factors directly as prothrombin complex concentrate (PCC), covered in full in the anticoagulant reversal chapter.
The forms, and where vitamin K comes from
Vitamin K comes in two natural forms. K1 (phytomenadione, also spelled phytonadione) is the plant form, abundant in green leafy vegetables, and it is the form used therapeutically — when a doctor "gives vitamin K," this is it. K2 (menaquinone) is made by the bacteria that colonize the large intestine, a genuinely useful contribution from the gut flora. That bacterial source explains one of the classic deficiency causes: a long course of broad-spectrum antibiotics can wipe out the very bacteria that were quietly topping up the body's vitamin K. Being fat-soluble, dietary vitamin K also depends on normal fat absorption to get into the body at all — a fact that sets up the whole deficiency story below.
- Vitamin K is the cofactor for gamma-carboxylation, which lets clotting factors bind calcium and work.
- Vitamin-K-dependent factors: II, VII, IX, X — plus anticoagulant proteins C and S.
- VKOR recycles vitamin K back to its active reduced form after each use.
- Warfarin inhibits VKOR → depletes reduced vitamin K → non-functional factors → anticoagulation (measured by INR/PT).
- K1 (phytomenadione) is the plant/therapeutic form; K2 (menaquinone) is made by gut bacteria.
- Vitamin K is fat-soluble, so its absorption depends on normal fat/bile handling.
Deficiency: a bleeding tendency
Run the mechanism forwards and the clinical picture writes itself. If vitamin K is the finishing step for factors II, VII, IX and X, then a shortage of it produces exactly one thing: functionally deficient clotting factors and a bleeding tendency. The laboratory signature is a prolonged prothrombin time and a raised INR (factor VII, being shortest-lived, drops first, so the PT-based INR moves earliest). Clinically it can range from easy bruising and mucosal bleeding to serious haemorrhage. The causes group neatly by mechanism. Fat malabsorption is the big one — because vitamin K needs fat and bile to be absorbed, any condition that impairs fat handling starves the body of it: cholestasis and obstructive jaundice (no bile reaching the gut), coeliac disease, chronic pancreatic insufficiency, and cystic fibrosis. This is the natural bridge to the Gastrointestinal section, where malabsorption is dissected in detail. The other causes: broad-spectrum antibiotics (killing the K2-producing flora), genuinely poor dietary intake, and — the pharmacological cause — warfarin itself, which manufactures a functional deficiency on purpose.
The clinical uses of vitamin K
Three situations put vitamin K (phytomenadione) into a prescriber's hands. First, reversing warfarin: the dose and route are matched to the urgency and the INR. A modestly high INR with no bleeding may need only a small oral dose or simply withholding warfarin; a very high INR or active bleeding calls for slow intravenous vitamin K, and for major bleeding it is combined with prothrombin complex concentrate to cover the hours vitamin K needs to work. Second, treating established deficiency bleeding from any of the malabsorptive or antibiotic causes above — replace the vitamin and the clotting normalizes. Third, and most iconic, neonatal prophylaxis. Newborns start life vitamin-K deficient for three reasons that stack: the placenta transfers it poorly, the newborn gut is sterile so there is no K2-producing flora yet, and breast milk is low in vitamin K. That leaves them exposed to vitamin K deficiency bleeding (haemorrhagic disease of the newborn), whose worst form is bleeding into the brain. The answer — one of the great routine wins of paediatrics — is a single intramuscular dose of vitamin K given to every baby at birth. This is the direct link to the Obstetrics & paediatrics section.
Long-acting rodenticides — the "superwarfarins" such as brodifacoum — are chemical cousins of warfarin that block VKOR far more potently and stubbornly. A person poisoned with one (accidentally, or deliberately) develops severe anticoagulation that can last weeks to months, because the compound clings to the liver and keeps blocking VKOR long after ordinary warfarin would have cleared. The treatment is the same antidote, scaled up dramatically: high-dose vitamin K, often oral, continued for weeks and titrated against the INR — sometimes with PCC for acute bleeding. It is the antidote relationship stretched to its extreme, and it cross-links to the Toxicology section.
- Deficiency = functionally deficient factors II/VII/IX/X → bleeding tendency, raised INR/PT.
- Main causes: fat malabsorption (cholestasis, coeliac, pancreatic insufficiency, CF), antibiotics, poor intake, warfarin.
- Reversing warfarin: oral or slow IV vitamin K by urgency; add PCC for major bleeding (vitamin K takes hours).
- Newborns are vitamin-K deficient (poor placental transfer, sterile gut, low breast-milk content).
- Routine IM vitamin K at birth prevents haemorrhagic disease of the newborn — a major public-health win.
- IV phytomenadione can cause anaphylactoid reactions — give it slowly.
- Giving vitamin K for a bleeding warfarin patient and expecting instant reversal — it takes hours to build new factors, so major bleeding needs PCC (or fresh frozen plasma) alongside it.
- Reversing a warfarin patient with an excessive dose of vitamin K when they still need anticoagulation — over-correcting makes them refractory to re-warfarinization for days.
- Pushing phytomenadione as a rapid IV bolus — it can trigger an anaphylactoid reaction; it must be given by slow IV infusion.
A 70-year-old on long-term warfarin presents with a major gastrointestinal bleed and an INR of 8. What is the most appropriate immediate management?
- Vitamin K is the cofactor for gamma-carboxylation of clotting factors II, VII, IX, X (and proteins C/S), letting them bind calcium and work; VKOR recycles it.
- Warfarin inhibits VKOR → non-functional factors → anticoagulation (INR); vitamin K (phytomenadione) is its antidote, and superwarfarin poisoning needs prolonged high-dose vitamin K.
- Deficiency causes a bleeding tendency with a raised INR; causes are fat malabsorption, broad-spectrum antibiotics, poor intake, and warfarin.
- Newborns are vitamin-K deficient and get routine IM vitamin K to prevent haemorrhagic disease of the newborn; reversing major warfarin bleeding needs vitamin K plus PCC because vitamin K takes hours.
- Rang & Dale's Pharmacology — Haemostasis and thrombosis: vitamin K and the coumarin anticoagulants.
- Katzung — Basic & Clinical Pharmacology: Drugs Used in Disorders of Coagulation (warfarin, vitamin K).
- British National Formulary (BNF) — Phytomenadione; warfarin and its reversal.
- British Society for Haematology — Guidelines on oral anticoagulation with warfarin and its reversal.
- NICE guideline NG24 / postnatal care — routine vitamin K prophylaxis for the newborn.
- Guyton & Hall Textbook of Medical Physiology — Haemostasis and blood coagulation; role of vitamin K.
